RxSight, Inc.
RXST· Nasdaq
Released Aug 5, 2026, after the close
10-Q filed Aug 5, 2026, 36 days after period end · 0001193125-26-335153
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $27.24M | $33.64M | $34.89M | $20.81M |
| Net Income | -$12.10M | -$11.79M | -$6.08M | -$13.80M |
| EPS Diluted |
RxSight, Inc. · CIK 1111485 · Engraved from SEC EDGAR
| -$0.29 |
| -$0.29 |
| -$0.16 |
| -$0.40 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.